{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 132,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide is part of an appendix section detailing clinical trial pipelines.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/41",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.94,
        "x": 0.03,
        "y": 0.195
      },
      "kind": "table",
      "text": "Trial, Population, Patients, Design, Endpoints, Status. Phase III LATIFY NCT05450692, Post-IO NSCLC, 594, Double-arm randomised, Primary endpoint: OS, FPCD: Q4 2022. Phase I/II NCT02264678, Solid tumours, 466, Module 1-5, Primary endpoints: safety, FPCD: Q4 2014",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13d34223-d0d8-4dfc-8c62-62a0f754063a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "ceralasertib (AZD6738, ATR inhibitor)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909cb012-b64d-492e-b1f6-8d50ee19eb55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.2,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Multiple cancers",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "040fbfe3-8ff9-4ce7-ae53-52a19da9dc5c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d0e2a5a0-33e1-4f74-aa89-51f83097832f",
      "evidence": "table/data: Trial, Population, Patients, Design, Endpoints, Status. Phase III LATIFY NCT05450692, Post-IO NSCLC, 594, Double-arm randomised, Primary endpoint: OS, FPCD: Q4 2022. Phase I/II NCT02264678, Solid tumours, 466",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}